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Abstract Children with chronic kidney disease (CKD) are
at increased risk for vaccine-preventable diseases. These
patients may have a reduced response to and/or reduced
duration of antibody after immunization and therefore
monitoring of antibody levels or titers is indicated for some
vaccines. In addition, pediatric CKD patients require
immunizations not routinely provided to healthy children.
Unfortunately, studies in pediatric CKD patients, including
those on dialysis and awaiting kidney transplantation, have
demonstrated sub-optimal immunization rates. In order to
minimize the risk for vaccine-preventable disease in pediat-
ric CKD patients, it is imperative that all who care for these
patients remain abreast of the recommended childhood
immunizationschedule,aswellasalterationstothisschedule
required for children with CKD, including end-stage kidney
disease. This article reviews recent changes to the recom-
mended childhood immunization schedule and alterations
and additions to this schedule recommended for children
with CKD. Where available, data on antibody response to
immunizations in children with CKD are presented.
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Introduction
The care of children with chronic kidney disease (CKD) is
very complex and, therefore, delivery of routine well-child
care, including immunizations, can be delayed or over-
looked. In fact, data from the United States Renal Data
System (USRDS) reveal that among prevalent end-stage
renal disease (ESRD) patients aged 0–19 years, 32% or
fewer received the seasonal influenza vaccine between
2005 and 2008, and 13% or fewer received vaccination
against Streptococcal pneumoniae [1]. The importance of
maximizing vaccination rates in CKD is highlighted by the
inclusion of monitoring of hepatitis B, influenza, and
pneumococcal vaccination rates among the indicators for
quality assessment and performance improvement programs
in the Centers for Medicaid & Medicare Services’ Con-
ditions for Coverage for ESRD facilities. In order to
optimally protect children with CKD against vaccine-
preventable disease, health care providers who care for
these children should be aware of the recent updates to the
standard recommendations for immunizations in childhood
as well as alterations to this schedule for children with
CKD.
Standard recommendations for immunizations
in childhood
The recommended immunization schedule for healthy
children in the USA is updated each year by the Center
for Disease Control (CDC) Advisory Committee on
Immunization Practices (ACIP) and the Committee on
Infectious Diseases of the American Academy of Pediatrics
(AAP) [2, 3]. These schedules, with explanatory footnotes,
are readily available to health care providers online (http://
www.aap.org/immunization/; http://www.cdc.gov/vaccines/
recs/schedules/child-schedule.htm). In 2011, the AAP and
ACIP continue to recommend immunization against diph-
theria, tetanus, pertussis, Hemophilus influenzae type b,
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and hepatitis B for all healthy children. [2, 3] Recent
modifications to this schedule include that the quadrivalent
human papillomavirus (HPV4) is now recommended for
males beginning at age 9 years [2–4]. Females may receive
either HPV4 or the bivalent vaccine (HPV2) typically
beginning at age 11 years, although it may be given as early
as age 9 years [2, 3]. In January 2011, the recommendation
for a second dose of the quadrivalent meningococcal
conjugate vaccine (MCV4) was added to the schedule [5].
It is now recommended that the initial MCV4 dose be given
to adolescents, preferably at age 11 or 12 years, with a
booster dose at age 16 years. A single dose at age 13
through 18 may be given to patients not vaccinated at age
11 or 12 years [5]. Finally, the 2011 schedule recommends
the substitution of the 13-valent conjugated pneumococcal
vaccine (PCV13) for the previously recommended 7-valent
conjugated pneumococcal vaccine (PCV7) [6, 7].
In addition to the annually updated recommendations for
healthy children, health care providers caring for children
with CKD should be aware of a guideline for vaccinating
patients on dialysis and with CKD, which was published by
the CDC in 2006 and which is available on the CDC
website. (http://www.cdc.gov/vaccines/pubs/downloads/
b_dialysis_guide-508.pdf). [8] In general, children with
CKD should receive all of the recommended childhood
immunizations according to the standard schedule, when-
ever possible. However, the live-viral vaccines (rotavirus
vaccine, varicella vaccine, measles, mumps, and rubella
vaccine, and the live-attenuated influenza vaccine) should
be avoided in patients who require treatment with immu-
nosuppressive medication, including those with status post-
kidney transplant. In the following sections, available data
on the antibody response to the various vaccines in
pediatric CKD patients will be provided, and any modifi-
cation of the standard schedule that may be required for
children with CKD will be discussed.
Immunizations in children with CKD
Diphtheria, tetanus and pertussis vaccine
Immunization against diphtheria, tetanus and pertussis has
long been recommended for healthy infants [2, 3]. The
vaccination series includes a total of five doses, the first
four of which are given at ages 2, 4, 6, and 15–18 months,
and the fifth at age 4–6 years [2, 3]. There are several
studies that suggest that children and young adults with
CKD, including those on dialysis, have sub-optimal
seroconversion rates following immunization with diphthe-
ria and tetanus toxoids and whole-cell pertussis (DTP)
vaccines [9–11]. However, a multi-center studied performed
in infants vaccinated with DTP while on dialysis revealed
protective antibody titers to both diphtheria and tetanus
toxoids in seven of the eight patients (88%) [12]. Since
1997, the ACIP has recommended that vaccines containing
the less reactogenic acellular pertussis antigens (DTaP)
replace DTP [13]. In 2005, a tetanus toxoid, reduced
diphtheria, and acellular pertussis vaccine (Tdap) was
licensed, and the use of this vaccine has been recommended
to replace the tetanus diphtheria booster (Td) dose in
adolescents since 2006. [14] Although data on the response
to the acellular pertussis vaccines in children with CKD are
lacking, it is currently recommended that infants with CKD
receive DTaP according to the standard childhood schedule.
Given the data on older children on dialysis, efforts should
be made to ensure that immunization with Tdap and
subsequent booster immunizations are provided in a timely
fashion.
Hemophilus influenzae type b (Hib) conjugate vaccine
Immunization against Hemophilus influenzae type b (Hib)
is recommended for all infants, with a four-dose series
beginning at age 2 months and ending between 12 and
15 months [2, 3]. A multi-center study in infants vaccinated
with Hib conjugate vaccine while on dialysis found that
nine of the ten (90%) patients had protective antibody
levels after vaccination and that antibody levels remained
protective for as long as 22 months post-vaccination [15]. A
second study found protective antibody levels 2 months
after the third dose of Hib conjugate vaccine in all 42
pediatric dialysis patients studied [16]. Thus, children with
CKD should receive this vaccine according to the standard
schedule.
Hepatitis B vaccine
Vaccination against hepatitis B is currently recommended
for all infants, with the first dose given to newborns before
hospital discharge [2, 3]. The second dose is to be given at
age 1 or 2 months, with a final dose between 6 and
18 months of age [2, 3]. Because dialysis, and hemodialysis
in particular, is associated with a significantly increased risk
for hepatitis B infection, every effort should be taken to
minimize that risk with vaccination [8, 17]. Unfortunately, a
suboptimal response to hepatitis B vaccine and a more
rapid decline in anti-hepatitis B antibody levels after
immunization have been well-documented among adult
dialysis patients and, therefore, the ACIP recommends that
adult patients on dialysis receive an augmented dose of
40 μg of either Recombivax HB (Merck & Co. Whitehouse
Station, NJ) or Engerix-B (GlaxoSmithKline, London, UK)
[8, 17]. Studies in adult CKD patients suggest that the
adjuvant 3-O-desacyl-40-monophosphoryl lipid A may
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an adjuvanted hepatitis B vaccine has been licensed in
Europe for use in adult CKD patients [18, 19]. However,
this vaccine is not currently in use in the USA, and there are
no studies of the vaccine in children with CKD [18, 19].
Data regarding the response to standard recombinant
hepatitis vaccines in pediatric CKD are limited. One study
vaccinated 62 children on dialysis or status post-kidney
transplant with a three-dose series of 5 μg (age <10 years)
or 10 μg (age >10 years) hepatitis B surface antigen
(HbsAg) [16]. Antibody levels obtained 2 months after the
final immunization were protective in 60/62 (97%) patients
[16]. In a multi-center study performed by the Southwest
Pediatric Nephrology Study Group, 78 pediatric patients
with CKD pre-dialysis, on dialysis, or with status post-
kidney transplant were given three immunizations of 20 μg
HbsAg after which 91% of patients had a protective titer
of >10 mIU/ml. [20] A lower percentage of patients
immunized post-transplant had protective antibody levels
in comparison with those with CKD pre-dialysis or on
dialysis (66.7 vs. 96.4%) [20]. In addition, mean geometric
mean antibody titers after three immunizations tended to be
higher in patients with CKD pre-dialysis than in patients on
dialysis or post-transplant, leading the authors to suggest
that at least two immunizations be given prior to the point
at which dialysis or transplant are necessary, whenever
possible [20].
Although these data suggest that pediatric CKD patients
may benefit from an augmented dose of hepatitis B vaccine,
at present the ACIP recommends that CKD and dialysis
patients younger than 20 years of age receive hepatitis B
immunization according to the standard schedule, with the
caveat that “higher doses might be more immunogenic” in
pediatric hemodialysis patients [8, 11, 21]. Post-vaccination
testing is recommended 1–2 months after the primary series
is completed, with up to three additional doses if protective
antibody levels (>10 mIU/ml) are not achieved [8, 11].
Antibody levels should then be measured annually and
booster doses provided to patients whose antibody levels
fall below protective [8].
Inactivated polio virus vaccine
Since 1999, AAP and ACIP recommendations have
specified that only inactivated polio virus (IPV) vaccine,
rather than the live-attenuated oral polio vaccine, be used
for routine immunization in all children beginning at age
2 months, with a second dose at 4 months, a third dose
between 6 and 18 months, and the final dose between 4 and
6 years of age [2, 3, 22]. Although IPV vaccine should
routinely be delivered to infants with CKD, there are no
studies documenting the response to this vaccine in this
patient population. A study performed in older children on
dialysis measured antibody levels after vaccination with
IPV vaccine and found that 42/49 (86%) patients either had
protective antibody levels to all three serotypes prior to
vaccination or had at least a fourfold increase in antibody
levels following immunization [23]. Because this vaccine
contains only inactivated virus, it may be given to CKD
patients who are also on immunosuppressive medications
as well as their household contacts.
Measles, mumps, rubella vaccine
Vaccination against measles, mumps and rubella (MMR) is
recommended for all children between the ages of 12 and
15 months, with a second dose typically between 4 and
6 years of age [2, 3]. MMR vaccine is a live, attenuated
viral vaccine and as such should be avoided in children
with CKD if they are receiving immunosuppressive
therapy, including corticosteroids at a dose greater than
2 mg/kg body weight or 20 mg total daily or on alternate
days for more than 14 days [24]. Once corticosteroids are
discontinued, it is generally recommended that MMR
vaccination be delayed for at least 1 month. [24]I n
addition, this live-viral vaccine is contraindicated in the
immunosuppressed patient status post-kidney transplant
[24].
There have been several studies evaluating the response
to MMR in pediatric CKD patients, including a study of ten
dialysis patients vaccinated with MMR between 15 and
33 months of age following which only 70% developed
protective titers to measles, 50% to mumps, 80% to rubella,
and only three of then (30%) to all three viruses [25]. An
additional study vaccinated nine infants, six of whom were
on dialysis, at a mean age of 11.6 months [26]. Eight of
these patients were subsequently transplanted at a mean age
of 16 months, and at the time of transplantation, 89% had
protective titers to measles, 88% to mumps, 100% to
rubella, and 88% to all three viruses [26]. In a third study,
positive antibody titers were found in 100% of 62 pediatric
dialysis patients 2 months after immunization with MMR
[16]. Although these data suggest that many pediatric
patients on dialysis may respond well to MMR vaccine,
because immunization post-transplant is contraindicated,
antibody titers should be measured prior to proceeding to
transplant, and repeat vaccination should be given to
patients with negative titers [24].
Varicella zoster virus vaccine
Immunization with varicella zoster virus (VZV) vaccine
was first implemented in the USA in 1995, with a single
dose to be administered at 12–15 months of age [27].
However, outbreaks of varicella continued to occur, even in
settings with high vaccination coverage, and thus a second
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was added to the routine childhood vaccination program in
2006 [28].
VZV vaccine is another live, attenuated viral vaccine
and is therefore contraindicated in CKD patients on
immunosuppressive medication, including those status
post-kidney transplantation [27]. There have been several
studies evaluating the immunogenicity of this vaccine in
children with CKD, including studies using the previously
recommended single immunization with VZV vaccine
which demonstrated seroconversion rates of 85–88%,
compared to a rate of 99% in healthy children [29, 30].
Two multi-center, prospective studies evaluated antibody
levels in children with CKD after a two-dose regimen of
VZV vaccine [31, 32]. Both studies revealed that nearly all
patients seroconverted after the second dose of vaccine,
with a 98% seroconversion rate in one study and 100% in
the other [31, 32]. Few infants were included in these
studies, however, and thus seroconversion rates in infants
and toddlers with CKD after either a one- or two-dose
regimen are not known. Given the significant risk for
morbidity and mortality from varicella infection status
post-kidney transplantation, it is reasonable to consider
measuring antibody levels prior to kidney transplantation in
any patient without a history of wild-type infection and to
provide supplemental vaccination if positive antibody titers
are not demonstrated.
Pneumococcal vaccine
Immunization against Streptococcus pneumonia using the
23-valent polysaccharide pneumococcal vaccine (PPSV23)
has been recommended for children with nephrotic syn-
drome since 1989 and for children with CKD since 1997, as
these patients are considered to be at high risk for the
development of invasive pneumococcal infection [33, 34].
This vaccine is poorly immunogenic in infants, however,
and therefore its use is limited to children 24 months and
older [33, 34]. In 2000, a conjugated pneumococcal
vaccine, PCV7, which is highly immunogenic in infants,
was licensed for use in the USA, and subsequently routine
immunization with PCV7 at ages 2, 4, 6, and 12–15 months
was recommended for all children, including those with
CKD [35]. Studies of the PCV7 vaccine have revealed
adequate antibody response in children with CKD, those on
dialysis, and solid organ transplant recipients [36, 37].
As mentioned previously, in 2011 the AAP and ACIP
recommended that a newly licensed PCV13 replace the
PCV7 in both healthy children and those with kidney
disease, with the aim of expanding serotype coverage [2, 3,
6, 7]. The number and timing of doses for PCV13 in
children under 24 months is based on the number of
previous immunizations with PCV7 [6, 7]. For children
with kidney disease aged 24–71 months who received at
least three doses of either PCV7 or PCV13 before age
24 months, a single dose of PCV13 is recommended at least
8 weeks after the most recent dose [6, 7]. A two-dose series
of PCV13 is to be given to children with kidney disease
aged 24–71 months and to children either previously
unvaccinated or with fewer than three previous doses of
either conjugated vaccine (PCV7 or PCV13) [3, 4].
It continues to be recommended that children with CKD
and nephrotic syndrome over the age of 2 years receive
supplemental immunization with PPSV23 [6, 7]. The
vaccine should be given at least 8 weeks after the final
dose of PCV13 [6, 7]. Revaccination with PPSV23 had
previously been recommended after 3 years in children
younger than 10 years of age at the time of first PPSV23
vaccination, and 5 years after the initial immunization in
older children, but the new recommendations suggest a
second dose of PPSV23 after 5 years for all children with
CKD [6, 7].
For children ages 6 through 18 years of age with CKD,
the new recommendations suggest that a single dose of
PCV13 should be given regardless of their previous history
of PCV7 or PPSV23 [6, 7]. Children with CKD who have
not previously received PPSV23 should receive vaccination
with PPSV23 at least 8 weeks after PCV13, with a
repeat dose of PPSV23 after 5 years [6, 7]. The
recommended schedules according to age and history of
pneumococcal vaccination are provided in detail on the
AAP and CDC websites (http://www.aap.org; http://www.
cdc.gov/vaccines/recs/acip).
Hepatitis A vaccine, meningococcal vaccine, human
papillomavirus vaccine, and rotavirus vaccine
There are currently no data available on the response to the
hepatitis A, meningococcal, human papillomavirus (HPV)
or rotavirus vaccines in children with CKD, although
prospective studies of the response to HPV and the
tetravalent conjugated meningococcal vaccine in children
with CKD, including dialysis and transplant patients, are
currently underway (A. Neu, personal communication).
Children with CKD may receive these vaccines as
recommended for healthy children with the caveat that the
live-attenuated rotavirus vaccine be avoided in children on
immunosuppressive therapy.
Influenza vaccine
Influenza vaccination was previously recommended only
for high-risk populations, but annual vaccination against
influenza is now recommended for all children over the age
of 6 months [38]. High-risk populations, including children
with CKD, continue to be a priority for immunization [39].
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year based on the strains of viruses likely to circulate in the
upcoming year and, therefore, this vaccine must be given
annually, typically in the fall [39]. Children under the age
of 9 years who are receiving the influenza vaccine for the
first time should receive two doses, given at least 1 month
apart [39]. The influenza vaccine is available either as an
inactivated vaccine or a live, attenuated vaccine (LAIV).
However, the CDC currently recommends that persons on
dialysis and those with the status post-kidney transplant do
not receive LAIV. Therefore, only the inactivated vaccine
should be given to children on dialysis and status post-
kidney transplant [40].
There have been several studies evaluating vaccine
response in pediatric CKD patients. The majority of these
studies have focused on pediatric kidney transplant patients,
and although one study revealed a lower seroconversion
rate than in healthy siblings, two other studies have
demonstrated seroconversion rates that are similar between
transplant patients and controls [41–43]. One of these
studies also evaluated vaccine response in pediatric dialysis
patients and revealed equivalent seroconversion rates
between the study group and controls [42]. Although these
studies suggest that influenza vaccine produces a reason-
able response in pediatric CKD patients, because of the
significant risk for morbidity and mortality from influenza
i n f e c t i o ni nt h e s ep a t i e n t s , household contacts should
receive vaccination in an effort to decrease the risk for
exposure to wild-type influenza [39].
Summary
Children with CKD are at increased risk for vaccine-
preventable diseases. Unfortunately, CKD may also reduce
the immunologic response to some vaccines. It should also
be recognized that vaccine response does not necessarily
confer immunity, and there are reports of Hemophilus
influenzae infections and pneumococcal peritonitis despite
adequate antibody response to vaccines against the causal
pathogens [16]. Nevertheless, immunization remains one of
the cornerstones of prevention. Pediatric CKD patients
should receive all of the vaccines currently recommended
for healthy children according to the standard schedule,
with the exception of the avoidance of the live-viral
vaccines (rotavirus vaccine, MMR, VZV, LAIV) in patients
receiving immunosuppressive medication and the avoid-
ance of the LAIV in dialysis patients [24, 27, 40]. Because
MMR and VZV vaccines are contraindicated post-
transplant, every effort to provide immunization prior to
the introduction of immunosuppressive medication post-
transplantation should be made. In addition, protection
against MMR and VZV should be documented prior to
transplantation and revaccination considered in those
patients without protective antibody titers. The timing of
resumption of non-live vaccination series post-transplantation
is variable among centers, but many delay immunizations for
6 months post-transplant, as recommended by the American
Society of Transplantation (AST). [44]
Children with CKD are considered to be at high risk for
infection with hepatitis B, and data suggest that some of
these patients may benefit from an augmented dose of this
vaccine [8, 11, 20]. At the very least, antibody levels should
be monitored and additional doses provided if an antibody
level >10 mIU/ml is not achieved after completion of the
three shot series [11]. In addition, antibody levels should be
monitored yearly, with a booster dose if levels fall below
10 mIU/ml [11]. Pediatric CKD patients should receive
supplemental immunization with the 13-valent conjugated
and 23-valent polysaccharide pneumococcal vaccines
[6, 7]. The number and timing of these supplemental
vaccines depends on the patient’s age and vaccination
history. In addition, revaccination with PPSV23 is indicated
5 years after the initial vaccination. Finally, influenza
vaccines should be given annually to all pediatric CKD
patients older than 6 months and to their household contacts.
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Questions(answersareprovidedfollowingthereferencelist)
1.) Children with CKD require alteration or augmentation
to the standard immunization schedule for healthy
children for which of the following vaccines?
a. Diphtheria, tetanus and acellular pertussis accine
b. Hemophilus influenza type b vaccine
c. Human papillomavirus vaccine
d. 13-Valent pneumococcal vaccine
e. Conjugated meningococcal vaccine
2.) Which of the following vaccines is contraindicated
in children with CKD treated with immunosuppres-
sive medications, including those status post-kidney
transplant?
a. Diphtheria, tetanus and acellular pertussis
b. Human papillomavirus
c. Varicella zoster virus vaccine
d. Inactivated poliovirus vaccine
e. Conjugated meningococcal vaccine
3.) Which of the following statements regarding influenza
vaccination is TRUE?
a. Vaccination should be provided to children with
CKD every 5 years
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attenuated influenza virus vaccine
c. All household contacts of children with CKD
should receive annual influenza vaccine
d. Vaccination should be avoided in children with
CKD on immunosuppressive medication
e. Vaccination should only be provided to CKD
patients over the age of 24 months
4.) Annual measurement of antibody to which of the
following is recommended in children on dialysis?
a. Hepatitis B
b. Hepatitis A
c. Varicella zoster virus
d. Measles
e. Rubella
5.) Which of the following statements regarding the
PCV13 in pediatric CKD patients is TRUE?
a. It should be given only to children younger than
24 months of age
b. It may be given to children with previous vaccina-
tion with the PPSV23
c. It is not required in children with previous
vaccination with the PCV7
d. It should be repeated 5 years after the initial
immunization
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Answers:
1. d. 13-valent Pneumococcal Vaccine
2. c. Varicella zoster virus vaccine
3. c. All household contacts of children with CKD should receive
annual influenza vaccine
4. a. Hepatitis B
5. b. It may be given to children with previous vaccination with the
PPSV23
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